ImmPACT Bio to Present at the BIO Investor Forum

LOS ANGELES, Oct. 11, 2023 /PRNewswire/ -- ImmPACT Bio USA, Inc. ("ImmPACT BIO"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced that it will participate at the BIO Investor Forum, to be held from October 17-18, 2023 in San Francisco, CA.

Sumant Ramachandra, M.D., Ph.D., ImmPACT Bio's president and chief executive officer, will participate in a panel discussion entitled "Opportunities in Bispecific Therapy Development," on Tuesday, October 17, 2023 at 11:00 AM PT.

About ImmPACT Bio
ImmPACT Bio USA, Inc., is a clinical-stage company dedicated to the discovery of transformative chimeric antigen receptor (CAR) T-cell therapies that address key biological challenges in treating cancer and autoimmune diseases. The company's logic-gate-based CAR T-cell platforms, licensed from University of California, Los Angeles (UCLA) Technology Development Group, are specifically designed to prevent antigen escape, overcome the immunosuppressive tumor microenvironment, and deplete pathogenic B cells. The company's technology is based on the work of pioneering scientists Yvonne Chen, Ph.D., and Antoni Ribas, M.D., Ph.D., both from UCLA. For more information, visit www.immpact-bio.com.

SOURCE ImmPACT Bio